DARWIN EU® - Characterising the use of JAK inhibitors in Europe: a Drug Utilisation Study

Study type

• Study topic:
  Human medicinal product
• Study topic, other:
  JAK inhibitors
• Study type:
  Non-interventional study
• Scope of the study:
  Drug utilisation
• Data collection methods:
  Secondary use of data

Non-interventional study

• Non-interventional study design:
  Cohort

Study drug and medical condition

• Anatomical Therapeutic Chemical (ATC) code:
  (L01EJ) Janus-associated kinase (JAK) inhibitors

  Janus-associated kinase (JAK) inhibitors

  (L04AF) Janus-associated kinase (JAK) inhibitors

  Janus-associated kinase (JAK) inhibitors

Population studied

• Short description of the study population:
  The population level cohort study will include all subjects available in the selected databases from 1st January 2017 until the most recent data lock of their respective databases, with at least 365 days of data visibility. ; The patient level cohort study will include all JAKi new users from the 1st January 2017 until the most recent data lock of their respective databases, with at least 365 days of data visibility.

Study design details

• Study design:
  - Population level cohort study (objective 1) ; - New user cohort study (objectives 2);
• Main study objective:
  1. To estimate the incidence of new JAKi use, overall and for each individual JAKi ingredient.; 2. To characterise new JAKi users and treatment for each individual JAKi ingredient, over all indications and stratified by indication. ;